19 results
Thumbnail

D1.244 - Clinical heterogeneity of pediatric atopic dermatitis: latent class analysis

Thumbnail

D1.241 - Clinical and Immunological Phenotypes of Alopecia Areata in Children with Atopic Dermatitis

Thumbnail

D1.236 - The role of tissue resident memory cells in immunodermatological disorders: A Systematic Review

Thumbnail

D1.237 - Mental Health and Neurodevelopmental Comorbidities in Pediatric Atopic Dermatitis: A Retrospective Study and Literature-Based Perspective

Thumbnail

D1.245 - The role of advanced glycation end products as facilitating factors in the pathogenesis of atopic dermatitis in pediatric patients

Thumbnail

D1.246 - Characterization of Unmet Need for Targeted Precision Medication in Atopic Dermatitis Due to Inadequate Response or Adverse Reactions to Dupilumab

Thumbnail

D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region

Thumbnail

D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor

Thumbnail

D3.155 - Th2–Th17 immune shift following dupilumab therapy

Thumbnail

D3.160 - Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry

Thumbnail

D3.164 - Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis